search
pharmaceutical companies
Trends
- 1Kobayashi Pharmaceutical may be target of ¥500 billion buyout●Kobayashi Pharmaceutical, the firm that was at the center of a supplement contamination scandal involving suspected deat
Kobayashi Pharmaceutical, the Japanese company at the center of a supplement contamination scandal involving suspected deaths, is reportedly considering a potential buyout offer valued at more than ¥500 billion. The news puts the embattled Osaka-based drugmaker back in the spotlight, with attention on who might take over the firm and what it would mean for the company's future after the scandal damaged its reputation and finances.
- 2Weight-loss jab maker sponsors Vogue World, drawing criticism▼‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event
Critics are raising concerns after Novo Nordisk, the maker of the weight-loss injection Wegovy, sponsored Vogue World, a high-profile fashion event tied to Vogue magazine. Commentators have called the partnership 'problematic', arguing that a pharmaceutical weight-loss company backing a leading fashion publication risks glamorising slimming drugs and reinforcing pressure around body image at a time when such jabs are already controversial.
- 3WSJ warns U.S. tariffs are hurting American biotech●The U.S. Tariff Attack on U.S. Biotech https://www.wsj.com/opinion/the-u-s-tariff-attack-on-u-s-biotech-c3406b92?mod=rss
The Wall Street Journal's opinion section argues that U.S. tariff policy is damaging the domestic biotechnology industry, which the piece frames as an ironic case of Washington's trade measures attacking American companies. The article is being shared in economic and policy discussions, drawing attention to the tension between protectionist trade policy and the administration's stated goal of strengthening U.S. industrial and pharmaceutical sectors.
- 4European Capital Backs Colombian Biotech Firm for 250 Million Vaccines▼Europe Injects Capital into Colombian Biotech Firm to Produce 250 Million Vaccines
European investors are injecting capital into a Colombian biotechnology company with plans to produce 250 million vaccines. The deal positions Colombia as a growing player in global vaccine manufacturing and reflects Europe's interest in diversifying pharmaceutical production capacity beyond its borders, though details on the funding amount and timeline remain limited.